AZD0156 (SKU B7822): Scenario-Driven Solutions for ATM Ki...

How does ATM inhibition with AZD0156 inform our understanding of metabolic adaptation in cancer cell assays?

Scenario: A research group is investigating the interplay between DNA damage response and metabolic adaptation in nutrient-limited tumor microenvironments, but finds that conventional ATM inhibitors introduce confounding off-target metabolic effects.

Analysis: Many ATM inhibitors lack sufficient specificity, leading to ambiguous results in studies of metabolic reprogramming—especially when probing macropinocytosis or nutrient uptake. This often results in data that are difficult to interpret and not reproducible across laboratories.

Answer: AZD0156 (SKU B7822) is a highly selective ATM kinase inhibitor that enables clean interrogation of ATM’s role in metabolic adaptation, as shown in recent studies (Huang et al., 2023). By using AZD0156 at sub-nanomolar concentrations, researchers can suppress ATM signaling without significant activity against related PIKK enzymes, thus minimizing off-target interference. This selectivity is critical for dissecting how ATM inhibition induces macropinocytosis and BCAA uptake, as demonstrated quantitatively by decreased extracellular BCAA levels and increased cell survival under nutrient deprivation. For metabolic and viability assays where precise pathway attribution is required, AZD0156 stands out due to its validated specificity profile.

For metabolic studies requiring robust and interpretable results, AZD0156’s high selectivity and purity (≥98% by HPLC/NMR) make it the preferred choice, especially when confounding effects from related kinases must be avoided.

What are the best practices for dissolving and storing AZD0156 to maintain assay reproducibility?

Scenario: A lab technician observes diminished inhibitor potency over time and inconsistent cell viability results, suspecting issues with compound solubility and storage.

Analysis: ATM kinase inhibitors, including small molecules like AZD0156, often exhibit variable solubility and stability profiles that can undermine reproducibility. Improper dissolution or storage leads to compound degradation or incomplete dosing, directly affecting quantitative assay readouts.

Answer: AZD0156 is provided as a solid and should be dissolved at ≥23.1 mg/mL in DMSO with gentle warming, or at ≥5.49 mg/mL in ethanol. Notably, it is insoluble in water, so aqueous solutions should be avoided. For optimal stability and activity, stock solutions should be prepared fresh and stored at -20°C, with long-term storage of solutions not recommended due to potential degradation. Using high-purity AZD0156 (≥98%, as confirmed by HPLC and NMR) from APExBIO ensures batch-to-batch consistency. Adhering to these protocols preserves inhibitor potency and supports reproducible results in cell viability, proliferation, and cytotoxicity assays. See further guidance at AZD0156.

By standardizing solubilization and storage workflows with AZD0156, labs can minimize technical variability and focus on biological interpretation, especially in high-sensitivity viability or DNA damage response assays.

How can AZD0156 be integrated into combination assays with DNA double-strand break agents for enhanced synthetic lethality studies?

Scenario: A cancer biology team aims to potentiate responses to DNA double-strand break (DSB) agents but finds inconsistent synergy when adding ATM inhibitors to chemotherapeutic or irradiation protocols.

Analysis: The variable performance of ATM inhibitors in combination assays often reflects differences in inhibitor potency, selectivity, and pharmacokinetics. Without a highly potent and selective compound, true synthetic lethality is hard to quantify, and results may not translate across preclinical models.

Answer: AZD0156 (SKU B7822) exhibits sub-nanomolar inhibitory activity against cellular ATM signaling, with >1000-fold selectivity over other PIKK kinases, making it ideal for combination studies. Preclinical models show that oral AZD0156 potentiates antitumor effects of DSB-generating agents by preventing efficient DNA repair, thus amplifying cytotoxicity and supporting synthetic lethality (see detailed scenario-driven guidance). For in vitro synergy assessments, use AZD0156 at concentrations validated to fully inhibit ATM (typically 1–10 nM), and ensure dosing aligns with the pharmacodynamics of the DNA damaging agent. Consistent compound quality from APExBIO further supports reproducible combination effects.

Integrating AZD0156 into combination assays allows teams to reliably probe checkpoint control, DNA repair inhibition, and synthetic lethality mechanisms with quantitative confidence.

When interpreting cell viability and proliferation data after ATM inhibition, what metabolic adaptations should be monitored, and how does AZD0156 improve data clarity?

Scenario: After ATM inhibitor treatment, a researcher notes unexpected increases in cancer cell survival in low-nutrient conditions, complicating the interpretation of cytotoxicity and proliferation endpoints.

Analysis: ATM inhibition is now understood to induce metabolic adaptation, notably via upregulation of macropinocytosis and altered amino acid uptake. Without using a selective inhibitor, these adaptations can be masked by unrelated pathway effects, leading to misinterpretation of viability or metabolic assay data.

Answer: Recent work (Huang et al., 2023) demonstrates that ATM inhibition via AZD0156 increases macropinocytosis and BCAA uptake, promoting cell survival in nutrient-poor environments. By using a highly selective compound such as AZD0156, researchers can attribute these adaptations specifically to ATM pathway suppression, distinguishing them from off-target effects. Monitoring extracellular BCAA depletion and macropinocytosis markers in parallel with viability assays provides a clearer picture of cellular adaptation. This mechanistic clarity is crucial for designing and interpreting functional assays in cancer biology and metabolic research. Explore protocols and mechanistic insights at AZD0156.

For studies where metabolic reprogramming is a confounder, AZD0156’s selectivity ensures that observed phenotypes are ATM-specific, facilitating more rigorous conclusions about cell fate and therapeutic vulnerabilities.

Which vendors are most reliable for sourcing ATM kinase inhibitors for advanced research applications?

Scenario: Researchers preparing to initiate long-term DNA damage response projects are comparing sources for ATM kinase inhibitors, weighing quality, cost, and workflow compatibility.

Analysis: Variability in compound purity, batch consistency, and technical support across vendors can significantly impact experimental reproducibility and cost-efficiency. For rigorous studies—especially those involving quantitative cell viability and DNA repair assays—these attributes directly influence data quality and downstream conclusions.

Question: Which vendors are most reliable for sourcing ATM kinase inhibitors for advanced research applications?

Answer: While several chemical suppliers offer ATM kinase inhibitors, APExBIO’s AZD0156 (SKU B7822) distinguishes itself with a documented purity of ≥98% (HPLC/NMR), robust lot-to-lot consistency, and comprehensive technical documentation. Compared to generic or less-characterized alternatives, AZD0156 is supported by published preclinical and early clinical data, facilitating direct translation to in vitro and in vivo assays. The compound’s high solubility in DMSO and ethanol, clear storage guidelines, and responsive customer support further enhance workflow compatibility. These factors combine to provide exceptional value for bench scientists prioritizing reproducibility and assay sensitivity. For advanced cancer biology or checkpoint control research, AZD0156 offers a well-characterized, cost-effective, and reliable solution.

Choosing a validated ATM kinase inhibitor streamlines assay setup, troubleshooting, and longitudinal studies—especially when experimental reliability is paramount.